Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Monday, December 31, 2018.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROE needs at least three reported quarters before a meaningful chart is shown.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Aquestive Therapeutics, Inc.
Market Cap
$573.38M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$569.56M
Return on Equity (ROE)
40.62%
TTM Avg
9.52%
3Y Avg
-25.24%
5Y Avg
-32.61%
Market Cap
$579.88M
Return on Equity (ROE)
N/A
TTM Avg
44.05%
3Y Avg
44.05%
5Y Avg
44.05%
Market Cap
$561.67M
Return on Equity (ROE)
-26.37%
TTM Avg
-3503.18%
3Y Avg
-1722.33%
5Y Avg
3198.08%
Market Cap
$551.09M
Return on Equity (ROE)
-17.44%
TTM Avg
-97.25%
3Y Avg
-87.77%
5Y Avg
-77.06%
Market Cap
$596.36M
Return on Equity (ROE)
-60.79%
TTM Avg
-73.94%
3Y Avg
-62.04%
5Y Avg
-71.62%
Market Cap
$547.86M
Return on Equity (ROE)
0.44%
TTM Avg
-17.98%
3Y Avg
71.24%
5Y Avg
-6.51%
Market Cap
$519.25M
Return on Equity (ROE)
-19.35%
TTM Avg
-58.07%
3Y Avg
-51.86%
5Y Avg
-46.32%
Market Cap
$517.79M
Return on Equity (ROE)
-99.83%
TTM Avg
118.83%
3Y Avg
8.21%
5Y Avg
-14.12%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | $573.38M | N/A | N/A | N/A | N/A |
| CorMedix Inc. (CRMD)vs › | $569.56M | 40.62% | 9.52% | -25.24% | -32.61% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $579.88M | N/A | 44.05% | 44.05% | 44.05% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.67M | -26.37% | -3503.18% | -1722.33% | 3198.08% |
| Immix Biopharma, Inc. (IMMX)vs › | $551.09M | -17.44% | -97.25% | -87.77% | -77.06% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $596.36M | -60.79% | -73.94% | -62.04% | -71.62% |
| Delcath Systems, Inc. (DCTH)vs › | $547.86M | 0.44% | -17.98% | 71.24% | -6.51% |
| Altimmune, Inc. (ALT)vs › | $519.25M | -19.35% | -58.07% | -51.86% | -46.32% |
| Crescent Biopharma, Inc. (CBIO)vs › | $517.79M | -99.83% | 118.83% | 8.21% | -14.12% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $517.73M | -37.94% | -63.13% | -60.30% | -47.34% |
ROE
N/A
ROA
-59.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2018-12-31 | -608.89% |
| 2018-09-30 | -245.15% |
